NDTDI is a tricyclic tryptamine derivative which is thought to act as a serotonin receptor agonist, though its pharmacology has not been studied in detail. It is a structurally simplified analogue of LSD and is reported to retain similar effects, though with many times lower potency. It has been sold as a designer drug since 2016 and was first identified by a forensic laboratory in Slovenia in 2017.[1]
NDTDI was made illegal in Latvia in March 2017.[2]